EU calls out drug companies on anti-competitive practices

The European Union has come out against several drug companies, saying that they were costing billions of dollars by delaying generics from making it to market. Some of the methods of delaying generics included paying off companies selling the generics and also amassing thousands of patents on a single drug in order to sue generic companies for violations of one or more patents. Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.